LMR Partners’s Aldeyra Therapeutics ALDX Stock Holding History

LMR Partners’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,585	Closed	-$254K	–	892
2023 Q1	$254K	Sell	25,585 -619	-2%	-$4.38K	﹤0.01%	828
2022 Q4	$182K	Buy	26,204 +8,893	+51%	+$50.8K	﹤0.01%	1005
2022 Q3	$92K	Hold	17,311	–	–	﹤0.01%	1058
2022 Q2	$69K	Buy	+17,311	New	+$59.5K	﹤0.01%	1132
2021 Q4	–	Sell	-52,671	Closed	-$462K	–	1142
2021 Q3	$462K	Sell	52,671 -220,184	-81%	-$2.02M	0.01%	816
2021 Q2	$3.09M	Buy	272,855 +250,175	+1,103%	+$3.01M	0.05%	270
2021 Q1	$269K	Buy	+22,680	New	+$261K	0.01%	750
2020 Q3	–	Sell	-10,540	Closed	-$44K	–	441
2020 Q2	$44K	Buy	+10,540	New	+$38.5K	﹤0.01%	535

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

LMR Partners's ALDX Position: Q2 2023 in Review

LMR Partners sold out of Aldeyra Therapeutics (ALDX) in Q2 2023, closing a stake of 25,585 shares — an estimated $254K sold.

LMR Partners first reported a position in ALDX in Q2 2020 and held it in 8 quarters. The position peaked at $3.09M in Q2 2021. 119 funds tracked by Wall St. Rank hold ALDX as of Q2 2023.

LMR Partners reported no remaining Aldeyra Therapeutics position as of Q2 2023 after selling out during the quarter.
LMR Partners sold 25,585 Aldeyra Therapeutics shares in Q2 2023, an estimated $254K.
LMR Partners first reported a position in Aldeyra Therapeutics in Q2 2020 and held it in 8 quarters.
LMR Partners's Aldeyra Therapeutics position peaked at $3.09M in Q2 2021.
119 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.